Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01194908 | Re-expression of ER in Triple Negative Breast Cancers | terminated | Phase 1 / Phase 2 | 5 | Emory UniversityOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00719901 | Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2015 | clinicaltrials |
| NCT00511576 |
| Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors |
| terminated |
| Phase 1 |
| 54 |
| Mirati Therapeutics Inc.INDUSTRY |
| 1 |
| Jan 8, 2015 |
| clinicaltrials |
| NCT00975767 | A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer | terminated | Phase 1 | 126 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jan 8, 2015 | clinicaltrials |
| NCT01400451 | Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) | terminated | Phase 1 | 18 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 1, 2015 | clinicaltrials |
| NCT00375453 | Dose Escalation Study of SH U04722 in Solid Tumors | terminated | Phase 1 | 10 | BayerINDUSTRY | 1 | Dec 31, 2014 | clinicaltrials |
| NCT00072137 | Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy | terminated | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01035216 | A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) | terminated | Phase 1 | 18 | SBI Biotech Co., Ltd.INDUSTRY | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01378481 | High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00622479 | Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia. | terminated | Phase 1 | 12 | BayerINDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00649584 | A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies | terminated | Phase 1 | 44 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00354523 | Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma | terminated | Phase 1 / Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 17, 2014 | clinicaltrials |
| NCT01291784 | Anti-TGF-beta Therapy in Patients With Myelofibrosis | terminated | Phase 1 | 3 | John MascarenhasOTHER | 1 | Dec 8, 2014 | clinicaltrials |
| NCT01404702 | Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma | terminated | Phase 1 | 4 | University of Alabama at BirminghamOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT01329549 | Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC) | terminated | Phase 1 | 2 | Boehringer IngelheimINDUSTRY | 1 | Nov 27, 2014 | clinicaltrials |
| NCT01238029 | Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer(CELAVIE) | terminated | Phase 1 | 12 | Sponsor GmbHOTHER | 1 | Nov 21, 2014 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 | clinicaltrials |
| NCT00753220 | Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer(CRITICAL) | terminated | Phase 1 / Phase 2 | 7 | Bostwick LaboratoriesINDUSTRY | 1 | Nov 4, 2014 | clinicaltrials |
| NCT02136342 | Phase 1 Trial of Chlorogenic Acid in Patients With Advanced Cancer | terminated | Phase 1 | — | Chinese Academy of Medical SciencesOTHER | 0 | Oct 21, 2014 | clinicaltrials |
| NCT01020305 | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | Sandy SrinivasOTHER | 1 | Oct 13, 2014 | clinicaltrials |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2014 | clinicaltrials |
| NCT01149434 | Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers | terminated | Phase 1 / Phase 2 | 19 | University of UtahOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT01065623 | Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors | terminated | Phase 1 | 2 | BayerINDUSTRY | 1 | Oct 1, 2014 | clinicaltrials |
| NCT02254044 | Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus | terminated | Phase 1 | 7 | Boehringer IngelheimINDUSTRY | 0 | Oct 1, 2014 | clinicaltrials |
| NCT01835184 | Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery | terminated | Phase 1 | 5 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2014 | clinicaltrials |
| NCT00892242 | Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer | terminated | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Sep 22, 2014 | clinicaltrials |
| NCT00675428 | Study of Natalizumab in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | BiogenINDUSTRY | 1 | Sep 19, 2014 | clinicaltrials |
| NCT02127372 | Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571 | terminated | Phase 1 / Phase 2 | 43 | Duke UniversityOTHER | 0 | Sep 15, 2014 | clinicaltrials |
| NCT01333137 | A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin | terminated | Phase 1 | 11 | Piramal Enterprises LimitedINDUSTRY | 1 | Sep 4, 2014 | clinicaltrials |
| NCT00724100 | A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 46 | Albany Molecular Research, Inc.INDUSTRY | 1 | Aug 27, 2014 | clinicaltrials |
| NCT02215044 | Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer | terminated | Phase 1 | 12 | Boehringer IngelheimINDUSTRY | 0 | Aug 13, 2014 | clinicaltrials |
| NCT02209701 | Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors | terminated | Phase 1 | 3 | Boehringer IngelheimINDUSTRY | 0 | Aug 6, 2014 | clinicaltrials |
| NCT02209727 | Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 | 9 | Boehringer IngelheimINDUSTRY | 0 | Aug 6, 2014 | clinicaltrials |
| NCT00787852 | A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 11 | Brown UniversityOTHER | 1 | Jul 30, 2014 | clinicaltrials |
| NCT00005072 | Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer | terminated | Phase 1 / Phase 2 | 25 | VicalINDUSTRY | 1 | Jul 29, 2014 | clinicaltrials |
| NCT02199886 | Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection | terminated | Phase 1 | 6 | Boehringer IngelheimINDUSTRY | 0 | Jul 25, 2014 | clinicaltrials |
| NCT01534949 | Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial(Triad-DLBCL) | terminated | Phase 1 | 1 | CelltrionINDUSTRY | 1 | Jul 23, 2014 | clinicaltrials |
| NCT01123304 | Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma | terminated | Phase 1 | 18 | MorphotekINDUSTRY | 1 | Jul 17, 2014 | clinicaltrials |
| NCT01212276 | A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma | terminated | Phase 1 | 18 | MorphotekINDUSTRY | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | terminated | Phase 1 | 35 | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT00002948 | High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer | terminated | Phase 1 | — | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT01664273 | Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer | terminated | Phase 1 | 7 | Copenhagen University Hospital at HerlevOTHER | 1 | Jun 20, 2014 | clinicaltrials |
| NCT01360827 | EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 1 | 13 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Jun 17, 2014 | clinicaltrials |
| NCT01631279 | A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | Proacta, IncorporatedINDUSTRY | 2 | Jun 16, 2014 | clinicaltrials |
| NCT00544648 | Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC | terminated | Phase 1 / Phase 2 | 13 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 9, 2014 | clinicaltrials |
| NCT00729833 | Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors | terminated | Phase 1 | 45 | PfizerINDUSTRY | 1 | Jun 9, 2014 | clinicaltrials |
| NCT00671554 | Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma | terminated | Phase 1 / Phase 2 | 3 | Prisma Health-UpstateOTHER | 1 | Jun 4, 2014 | clinicaltrials |
Data updated 24 days agoSource updated Jan 26, 2015source: clinicaltrials